Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

Presentation AHA 2024

Efficacy and safety of EdoxabaN in anticoagulant therapy after surgical Bioprosthetic vALVe replacement

Presenter: Chisato Izumi

November 17, 2024

News Conference News AHA 2024

ENBALV: Edoxaban Matches Warfarin After Bioprosthetic Valve Surgery

Yael L. Maxwell

November 17, 2024

News Daily News

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

Michael O'Riordan

October 20, 2022

News Daily News

Fewer Diabetic Complications Seen When NOACs Given for AF

L.A. McKeown

February 22, 2022

News Conference News CRT 2020

Small Study Hints Rivaroxaban Helps Cut Stroke in A-fib Patients Post-TAVR

L.A. McKeown

February 24, 2020

News Daily News

Intracranial Hemorrhage Outside of A-fib: Different NOACs, Different Risks

Todd Neale

August 13, 2018

News Daily News

NOACs May Carry Lower Risk of Intraocular Hemorrhage Than Warfarin

L.A. McKeown

January 02, 2018

News Conference News VIVA 2017

Apixaban May Be Better Choice Than Rivaroxaban for DVT Patients

L.A. McKeown

September 11, 2017

News Daily News

Addition of Biomarkers May Fine Tune Risk Stratification in Atrial Fibrillation

Michael O'Riordan

October 07, 2016

News Daily News

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

Michael O'Riordan

August 18, 2016

News Conference News ACC 2016

Comparing the Novel Oral Anticoagulants: Effectiveness Similar, but Apixaban May Come With Less Bleeding

Todd Neale

April 06, 2016

News Industry News

UK launch for Daiichi's bloodthinner Lixiana

July 10, 2015

News Daily News

La Dosis Alta de Edoxaban es Igual de Eficaz que la Warfarina en la Prevención de ACV por FA

Yael L. Maxwell

June 27, 2014

News Daily News

High-Dose Edoxaban as Effective as Warfarin for Stroke Prevention in A-fib

Yael L. Maxwell

June 27, 2014

Presentation

Cerebrovascular Events in 21,105 Patients with A-fib Randomized to Edoxaban Versus Warfarin

Presenter: Robert P. Giugliano

June 24, 2014

News Daily News

ROCKET AF Substudy: Rivaroxaban Safe, Effective in East Asian Patients

L.A. McKeown

April 29, 2014

Advertisement

Efficacy and safety of EdoxabaN in anticoagulant therapy after surgical Bioprosthetic vALVe replacement

ENBALV: Edoxaban Matches Warfarin After Bioprosthetic Valve Surgery

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

Fewer Diabetic Complications Seen When NOACs Given for AF

Small Study Hints Rivaroxaban Helps Cut Stroke in A-fib Patients Post-TAVR

Intracranial Hemorrhage Outside of A-fib: Different NOACs, Different Risks

NOACs May Carry Lower Risk of Intraocular Hemorrhage Than Warfarin

Apixaban May Be Better Choice Than Rivaroxaban for DVT Patients

Addition of Biomarkers May Fine Tune Risk Stratification in Atrial Fibrillation

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

Comparing the Novel Oral Anticoagulants: Effectiveness Similar, but Apixaban May Come With Less Bleeding

UK launch for Daiichi's bloodthinner Lixiana

La Dosis Alta de Edoxaban es Igual de Eficaz que la Warfarina en la Prevención de ACV por FA

High-Dose Edoxaban as Effective as Warfarin for Stroke Prevention in A-fib

Cerebrovascular Events in 21,105 Patients with A-fib Randomized to Edoxaban Versus Warfarin

ROCKET AF Substudy: Rivaroxaban Safe, Effective in East Asian Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content